文献速递类风湿关节炎

糖皮质激素在类风湿关节炎中的应用:现状与未来研究

Glucocorticoids in rheumatoid arthritis: current status and future studies.
PubMed 文献 · RMD Open · 2020-01-01

该综述回顾了糖皮质激素(GCs)治疗类风湿关节炎(RA)的文献及指南制定后的近期试验数据,指出最新EULAR和ACR推荐GCs作为传统合成改善病情抗风湿药(csDMARDs)的辅助治疗,使用最低剂量和最短时间,但剂量方案和给药途径仍不明确,并提出了日常实践建议和未来研究方向。

要点

  • GCs仍广泛用于RA,但毒性争议大,共识难以达成。
  • 最新EULAR/ACR推荐GCs作为csDMARDs辅助治疗,最低剂量最短时间。
  • 指南对剂量方案和给药途径仍相对模糊,需未来研究明确。

核心结论

  • GCs在RA治疗中仍占重要地位,但低剂量和极低剂量GCs的获益/风险比及桥接治疗最佳疗程等问题仍需未来研究以指导下一版推荐。

研究设计与样本

  • 本文为综述,描述当前推荐所依据的文献数据及指南起草后发表的近期试验数据,并提出日常实践建议和未来研究建议。

主要发现

  • 最新EULAR和ACR关于早期关节炎和RA管理的推荐主张GCs作为csDMARDs的辅助治疗,使用最低可能剂量和最短可能时间。
  • 推荐在剂量方案和给药途径方面仍相对模糊。

关键数值与推荐

  • EULAR和ACR最新推荐:GCs作为csDMARDs辅助治疗,使用最低可能剂量和最短可能时间。

临床怎么用

  • 临床可将GCs作为csDMARDs的辅助治疗,采用最低可能剂量和最短可能时间,但具体剂量方案和给药途径需结合个体情况。

局限性

  • 指南对剂量方案和给药途径相对模糊,低剂量和极低剂量GCs的获益/风险比及桥接治疗最佳疗程等未明确。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Since their first use for treating rheumatoid arthritis (RA) in the late 1940s, glucocorticoids (GCs) have been representing a substantial part of the therapeutic arsenal for RA. However, even if GCs are still widely prescribed drugs, their toxicity is discussed controversially, so obtaining consensus on their use in RA is difficult. Hence, the most recent European League Against Rheumatism and American College of Rheumatology recommendations on early arthritis and RA management advocate the use of GCs as adjunct treatment to conventional synthetic disease-modifying antirheumatic drugs, at the lowest dose possible and for the shortest time possible. However, the recommendations remain relatively vague on dose regimens and routes of administration. Here, we describe literature data on which the current recommendations are based as well as data from recent trials published since the drafting of the guidelines. Moreover, we make proposals for daily practice and provide suggestions for studies that could help clarifying the place of GCs in RA management. Indeed, numerous items, including the benefit/risk ratio of low-dose and very low-dose GCs and optimal duration of GCs as bridging therapy, remain on the research agenda, and future studies are needed to guide the next recommendations for RA.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Hua C, Buttgereit F, Combe B, et al. Glucocorticoids in rheumatoid arthritis: current status and future studies. RMD Open. 2020. PMID: 31958273. doi:10.1136/rmdopen-2017-000536

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。